J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill

The FDA on Friday signed off on Johnson & Johnson’s single-tablet combination therapy of macitentan and tadalafil for the treatment of pulmonary arterial hypertension (PAH) in adults. The drug will be sold under the brand name Opsynvi.